Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 356

1.

Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation.

Chua W, Purmah Y, Cardoso VR, Gkoutos GV, Tull SP, Neculau G, Thomas MR, Kotecha D, Lip GYH, Kirchhof P, Fabritz L.

Eur Heart J. 2019 Jan 7. doi: 10.1093/eurheartj/ehy815. [Epub ahead of print]

PMID:
30615112
2.

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.

De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators.

J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):97-104. doi: 10.2459/JCM.0000000000000737.

PMID:
30540648
3.

Development and validation of a score to detect paroxysmal atrial fibrillation after stroke.

Uphaus T, Weber-Krüger M, Grond M, Toenges G, Jahn-Eimermacher A, Jauss M, Kirchhof P, Wachter R, Gröschel K.

Neurology. 2019 Jan 8;92(2):e115-e124. doi: 10.1212/WNL.0000000000006727. Epub 2018 Dec 7.

PMID:
30530796
4.

Reply: Anticoagulants for Cardioembolism Prevention in Atrial Fibrillation Patients: Potential Bias From Real-World Studies.

Kirchhof P, Bach M, Camm AJ.

J Am Coll Cardiol. 2018 Nov 13;72(20):2546-2547. doi: 10.1016/j.jacc.2018.09.024. No abstract available.

PMID:
30442303
5.

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.

Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AG, Camm AJ.

Eur Heart J Cardiovasc Pharmacother. 2018 Nov 13. doi: 10.1093/ehjcvp/pvy041. [Epub ahead of print]

PMID:
30423165
6.

Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin.

Kotecha D, Pollack CV Jr, De Caterina R, Renda G, Kirchhof P.

J Am Coll Cardiol. 2018 Oct 16;72(16):1984-1986. doi: 10.1016/j.jacc.2018.07.083. No abstract available.

PMID:
30309478
7.

Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future.

Kotecha D, Bax JJ, Carrera C, Casadei B, Merkely B, Anker SD, Vardas PE, Kearney PP, Roffi M, Ros M, Vahanian A, Weidinger F, Beeri R, Budaj A, Calabrò P, Czerwinska-Jelonkiewicz K, D'Ascenzi F, De Potter T, Fox KF, Hartikainen J, McAdam B, Milicic D, Pasquet AA, Sionis A, Sohaib SMA, Tsioufis C, Verhorst PMJ, Kirchhof P; ESC Scientific Document Group ; 2016 ESC Education Conference .

Eur Heart J. 2018 Jan 31. doi: 10.1093/eurheartj/ehy058. [Epub ahead of print]

PMID:
30226525
8.

Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries.

Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, Siller-Matula J, Schnabel RB, Cemin R, Kirchhof P, De Caterina R.

Int J Cardiol. 2018 Nov 1;270:160-166. doi: 10.1016/j.ijcard.2018.06.098. Epub 2018 Jun 28.

PMID:
30220376
9.

Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study.

Reinecke H, Jürgensmeyer S, Engelbertz C, Gerss J, Kirchhof P, Breithardt G, Bauersachs R, Wanner C.

BMJ Open. 2018 Sep 10;8(9):e022690. doi: 10.1136/bmjopen-2018-022690.

10.

Safety and efficacy of uninterrupted vs. minimally interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: two sides of the same coin?

Di Biase L, Kirchhof P, Romero J.

Europace. 2018 Jul 24. doi: 10.1093/europace/euy172. [Epub ahead of print] No abstract available.

PMID:
30052953
11.

Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG; XANTUS Investigators.

Europace. 2018 Jul 19. doi: 10.1093/europace/euy160. [Epub ahead of print]

PMID:
30052894
12.

Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.

Romero J, Cerrud-Rodriguez RC, Diaz JC, Michaud GF, Taveras J, Alviz I, Grupposo V, Cerna L, Avendano R, Kumar S, Kirchhof P, Natale A, Di Biase L.

Europace. 2018 Oct 1;20(10):1612-1620. doi: 10.1093/europace/euy133.

PMID:
29982383
13.

Global Prospective Safety Analysis of Rivaroxaban.

Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, Hess S, Camm AJ; Global XANTUS program Investigators.

J Am Coll Cardiol. 2018 Jul 10;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058.

14.

Multi-ethnic genome-wide association study for atrial fibrillation.

Roselli C, Chaffin MD, Weng LC, Aeschbacher S, Ahlberg G, Albert CM, Almgren P, Alonso A, Anderson CD, Aragam KG, Arking DE, Barnard J, Bartz TM, Benjamin EJ, Bihlmeyer NA, Bis JC, Bloom HL, Boerwinkle E, Bottinger EB, Brody JA, Calkins H, Campbell A, Cappola TP, Carlquist J, Chasman DI, Chen LY, Chen YI, Choi EK, Choi SH, Christophersen IE, Chung MK, Cole JW, Conen D, Cook J, Crijns HJ, Cutler MJ, Damrauer SM, Daniels BR, Darbar D, Delgado G, Denny JC, Dichgans M, Dörr M, Dudink EA, Dudley SC, Esa N, Esko T, Eskola M, Fatkin D, Felix SB, Ford I, Franco OH, Geelhoed B, Grewal RP, Gudnason V, Guo X, Gupta N, Gustafsson S, Gutmann R, Hamsten A, Harris TB, Hayward C, Heckbert SR, Hernesniemi J, Hocking LJ, Hofman A, Horimoto ARVR, Huang J, Huang PL, Huffman J, Ingelsson E, Ipek EG, Ito K, Jimenez-Conde J, Johnson R, Jukema JW, Kääb S, Kähönen M, Kamatani Y, Kane JP, Kastrati A, Kathiresan S, Katschnig-Winter P, Kavousi M, Kessler T, Kietselaer BL, Kirchhof P, Kleber ME, Knight S, Krieger JE, Kubo M, Launer LJ, Laurikka J, Lehtimäki T, Leineweber K, Lemaitre RN, Li M, Lim HE, Lin HJ, Lin H, Lind L, Lindgren CM, Lokki ML, London B, Loos RJF, Low SK, Lu Y, Lyytikäinen LP, Macfarlane PW, Magnusson PK, Mahajan A, Malik R, Mansur AJ, Marcus GM, Margolin L, Margulies KB, März W, McManus DD, Melander O, Mohanty S, Montgomery JA, Morley MP, Morris AP, Müller-Nurasyid M, Natale A, Nazarian S, Neumann B, Newton-Cheh C, Niemeijer MN, Nikus K, Nilsson P, Noordam R, Oellers H, Olesen MS, Orho-Melander M, Padmanabhan S, Pak HN, Paré G, Pedersen NL, Pera J, Pereira A, Porteous D, Psaty BM, Pulit SL, Pullinger CR, Rader DJ, Refsgaard L, Ribasés M, Ridker PM, Rienstra M, Risch L, Roden DM, Rosand J, Rosenberg MA, Rost N, Rotter JI, Saba S, Sandhu RK, Schnabel RB, Schramm K, Schunkert H, Schurman C, Scott SA, Seppälä I, Shaffer C, Shah S, Shalaby AA, Shim J, Shoemaker MB, Siland JE, Sinisalo J, Sinner MF, Slowik A, Smith AV, Smith BH, Smith JG, Smith JD, Smith NL, Soliman EZ, Sotoodehnia N, Stricker BH, Sun A, Sun H, Svendsen JH, Tanaka T, Tanriverdi K, Taylor KD, Teder-Laving M, Teumer A, Thériault S, Trompet S, Tucker NR, Tveit A, Uitterlinden AG, Van Der Harst P, Van Gelder IC, Van Wagoner DR, Verweij N, Vlachopoulou E, Völker U, Wang B, Weeke PE, Weijs B, Weiss R, Weiss S, Wells QS, Wiggins KL, Wong JA, Woo D, Worrall BB, Yang PS, Yao J, Yoneda ZT, Zeller T, Zeng L, Lubitz SA, Lunetta KL, Ellinor PT.

Nat Genet. 2018 Sep;50(9):1225-1233. doi: 10.1038/s41588-018-0133-9. Epub 2018 Jun 11.

15.

Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe.

Schnabel RB, Pecen L, Rzayeva N, Lucerna M, Purmah Y, Ojeda FM, De Caterina R, Kirchhof P.

J Am Heart Assoc. 2018 May 18;7(11). pii: e007559. doi: 10.1161/JAHA.117.007559.

16.

Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy.

Siller-Matula JM, Pecen L, Patti G, Lucerna M, Kirchhof P, Lesiak M, Huber K, Verheugt FWA, Lang IM, Renda G, Schnabel RB, Wachter R, Kotecha D, Sellal JM, Rohla M, Ricci F, De Caterina R; TEAM in AF group.

Int J Cardiol. 2018 Aug 15;265:141-147. doi: 10.1016/j.ijcard.2018.04.093. Epub 2018 Apr 22.

PMID:
29706429
17.

Expert opinion paper on atrial fibrillation detection after ischemic stroke.

Haeusler KG, Gröschel K, Köhrmann M, Anker SD, Brachmann J, Böhm M, Diener HC, Doehner W, Endres M, Gerloff C, Huttner HB, Kaps M, Kirchhof P, Nabavi DG, Nolte CH, Pfeilschifter W, Pieske B, Poli S, Schäbitz WR, Thomalla G, Veltkamp R, Steiner T, Laufs U, Röther J, Wachter R, Schnabel R.

Clin Res Cardiol. 2018 Oct;107(10):871-880. doi: 10.1007/s00392-018-1256-9. Epub 2018 Apr 27. Review.

PMID:
29704214
18.

Is there a CASTLE-AF on the hill?

Bono J, Kirchhof P.

Eur Heart J. 2018 Apr 21;39(16):1324-1325. doi: 10.1093/eurheartj/ehy172. No abstract available.

PMID:
29688436
19.

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.

Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, Sudworth M, Cater NB, Breazna A, Oldgren J, Kirchhof P.

Eur Heart J. 2018 Aug 21;39(32):2959-2971. doi: 10.1093/eurheartj/ehy148.

20.

Nitrite circumvents platelet resistance to nitric oxide in patients with heart failure preserved ejection fraction and chronic atrial fibrillation.

Borgognone A, Shantsila E, Worrall SM, Prompunt E, Loka T, Loudon BL, Chimen M, Ed Rainger G, Lord JM, Turner A, Nightingale P, Feelisch M, Kirchhof P, Lip GYH, Watson SP, Frenneaux MP, Madhani M.

Cardiovasc Res. 2018 Aug 1;114(10):1313-1323. doi: 10.1093/cvr/cvy087.

21.

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.

Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A, Fetsch T, Van Gelder IC, Gentlesk P, Grimaldi M, Hansen J, Hindricks G, Al-Khalidi HR, Massaro T, Mont L, Nielsen JC, Nölker G, Piccini JP, De Potter T, Scherr D, Schotten U, Themistoclakis S, Todd D, Vijgen J, Di Biase L.

Eur Heart J. 2018 Aug 21;39(32):2942-2955. doi: 10.1093/eurheartj/ehy176.

22.

Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes.

B Schnabel R, Pecen L, Engler D, Lucerna M, Sellal JM, Ojeda FM, De Caterina R, Kirchhof P.

Heart. 2018 Oct;104(19):1608-1614. doi: 10.1136/heartjnl-2017-312569. Epub 2018 Mar 17.

PMID:
29550771
23.

The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.

Verma A, Ha ACT, Kirchhof P, Hindricks G, Healey JS, Hill MD, Sharma M, Wyse DG, Champagne J, Essebag V, Wells G, Gupta D, Heidbuchel H, Sanders P, Birnie DH.

Am Heart J. 2018 Mar;197:124-132. doi: 10.1016/j.ahj.2017.12.007. Epub 2017 Dec 8.

PMID:
29447772
24.

The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy.

Pavlovic D, Kirchhof P, Fabritz L.

Eur Heart J. 2018 Aug 21;39(32):2997-2999. doi: 10.1093/eurheartj/ehy018. No abstract available.

25.

Phenotyping of Mice with Heart Specific Overexpression of A2A-Adenosine Receptors: Evidence for Cardioprotective Effects of A2A-Adenosine Receptors.

Boknik P, Drzewiecki K, Eskandar J, Gergs U, Grote-Wessels S, Fabritz L, Kirchhof P, Müller FU, Stümpel F, Schmitz W, Zimmermann N, Kirchhefer U, Neumann J.

Front Pharmacol. 2018 Jan 22;9:13. doi: 10.3389/fphar.2018.00013. eCollection 2018.

26.

Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference.

Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A, Arnar D, Atar D, Auricchio A, Bax J, Benussi S, Blomstrom-Lundqvist C, Borggrefe M, Boriani G, Brandes A, Calkins H, Casadei B, Castellá M, Chua W, Crijns H, Dobrev D, Fabritz L, Feuring M, Freedman B, Gerth A, Goette A, Guasch E, Haase D, Hatem S, Haeusler KG, Heidbuchel H, Hendriks J, Hunter C, Kääb S, Kespohl S, Landmesser U, Lane DA, Lewalter T, Mont L, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Pison L, Potpara T, Ravens U, Richard-Lordereau I, Rienstra M, Savelieva I, Schnabel R, Sinner MF, Sommer P, Themistoclakis S, Van Gelder IC, Vardas PE, Verma A, Wakili R, Weber E, Werring D, Willems S, Ziegler A, Hindricks G, Kirchhof P.

Europace. 2018 Mar 1;20(3):395-407. doi: 10.1093/europace/eux318.

27.

Stratified prevention: opportunities and limitations. Report on the 1st interdisciplinary cardiovascular workshop in Augsburg.

Kirchhof G, Lindner JF, Achenbach S, Berger K, Blankenberg S, Fangerau H, Gimpel H, Gassner UM, Kersten J, Magnus D, Rebscher H, Schunkert H, Rixen S, Kirchhof P.

Clin Res Cardiol. 2018 Mar;107(3):193-200. doi: 10.1007/s00392-017-1186-y. Epub 2017 Dec 16. Review.

28.

Training the next generation of cardiovascular leaders in health policy and economics.

Naci H, Kirchhof P, Vahanian A, Steffel J, Bardinet I, Mossialos E, Vardas P.

Eur Heart J. 2017 Dec 1;38(45):3332-3335. doi: 10.1093/eurheartj/ehx673. No abstract available.

PMID:
29206965
29.

Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?

Piccini JP, Kirchhof P.

Eur Heart J. 2018 Feb 7;39(6):450-452. doi: 10.1093/eurheartj/ehx567. No abstract available.

PMID:
29182747
30.

Outcome of left atrial appendage occlusion in high-risk patients.

Masoud A, Bartoletti S, Fairbairn T, Khurana A, Velavan P, Morrison WL, Khalatbari A, Aggarwal S, Sharma N, Kirchhof P, Gupta D.

Heart. 2018 Apr;104(7):594-599. doi: 10.1136/heartjnl-2017-312383. Epub 2017 Nov 9.

PMID:
29122931
31.

Recent advances in rhythm control for atrial fibrillation.

Bond R, Olshansky B, Kirchhof P.

F1000Res. 2017 Oct 3;6:1796. doi: 10.12688/f1000research.11061.1. eCollection 2017. Review.

32.

European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers.

Kotecha D, Chua WWL, Fabritz L, Hendriks J, Casadei B, Schotten U, Vardas P, Heidbuchel H, Dean V, Kirchhof P; European Society of Cardiology (ESC) Atrial Fibrillation Guidelines Taskforce, the CATCH ME consortium and the European Heart Rhythm Association (EHRA).

Europace. 2018 Feb 1;20(2):225-233. doi: 10.1093/europace/eux299. Review.

33.

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.

Camm AJ, Turpie AGG, Hess S, Amarenco P, Lambelet M, Haas S, van Eickels M, Kirchhof P; XANTUS Investigators.

Europace. 2018 Jun 1;20(6):e87-e95. doi: 10.1093/europace/eux127.

PMID:
29016755
34.

Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.

De Caterina R, Brüggenjürgen B, Darius H, Köhler S, Lucerna M, Pecen L, Renda G, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P.

Arch Cardiovasc Dis. 2018 Feb;111(2):74-84. doi: 10.1016/j.acvd.2017.04.007. Epub 2017 Sep 21.

PMID:
28942115
35.

ESC Apps for Atrial Fibrillation.

Kotecha D, Kirchhof P.

Eur Heart J. 2017 Sep 14;38(35):2643-2645. doi: 10.1093/eurheartj/ehx445. No abstract available.

36.

My atrial fibrillation is not your atrial fibrillation.

Kirchhof P, Sanders P.

Eur Heart J. 2017 Sep 7;38(34):2608-2611. doi: 10.1093/eurheartj/ehx389. No abstract available.

PMID:
28911191
37.

NOACs in Atrial Fibrillation.

Kirchhof P, Schroeder S; European Society of Cardiology Cardiovascular Roundtable.

Eur Heart J. 2017 Aug 14;38(31):2382-2385. doi: 10.1093/eurheartj/ehx407. No abstract available.

PMID:
28821171
38.

Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.

Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P.

Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3.

39.
40.

A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.

Kotecha D, Calvert M, Deeks JJ, Griffith M, Kirchhof P, Lip GY, Mehta S, Slinn G, Stanbury M, Steeds RP, Townend JN.

BMJ Open. 2017 Jul 20;7(7):e015099. doi: 10.1136/bmjopen-2016-015099.

41.

Management of atrial high-rate episodes detected by cardiac implanted electronic devices.

Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS.

Nat Rev Cardiol. 2017 Dec;14(12):701-714. doi: 10.1038/nrcardio.2017.94. Epub 2017 Jul 6. Review.

PMID:
28682320
42.

Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.

Pisters R, van Vugt SPG, Brouwer MA, Elvan A, Ten Holt WL, Zwart PAG, Kirchhof P, Crijns HJGM, Hemels MEW.

Neth Heart J. 2017 Oct;25(10):551-558. doi: 10.1007/s12471-017-1009-9.

43.

Innovation in cardiovascular disease in Europe with focus on arrhythmias: current status, opportunities, roadblocks, and the role of multiple stakeholders.

Prinzen FW, Dagres N, Bollmann A, Arnar DO, Bove S, Camm J, Casadei B, Kirchhof P, Kuck KH, Lumens J, Michel MC, Schwartz PJ, Van Vleymen B, Vardas P, Hindricks G.

Europace. 2018 May 1;20(5):733-738. doi: 10.1093/europace/eux095.

PMID:
28605436
44.

Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration.

Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, Albert CM, Anderson CS, Antoniou S, Benjamin EJ, Boriani G, Brachmann J, Brandes A, Chao TF, Conen D, Engdahl J, Fauchier L, Fitzmaurice DA, Friberg L, Gersh BJ, Gladstone DJ, Glotzer TV, Gwynne K, Hankey GJ, Harbison J, Hillis GS, Hills MT, Kamel H, Kirchhof P, Kowey PR, Krieger D, Lee VWY, Levin LÅ, Lip GYH, Lobban T, Lowres N, Mairesse GH, Martinez C, Neubeck L, Orchard J, Piccini JP, Poppe K, Potpara TS, Puererfellner H, Rienstra M, Sandhu RK, Schnabel RB, Siu CW, Steinhubl S, Svendsen JH, Svennberg E, Themistoclakis S, Tieleman RG, Turakhia MP, Tveit A, Uittenbogaart SB, Van Gelder IC, Verma A, Wachter R, Yan BP; AF-Screen Collaborators.

Circulation. 2017 May 9;135(19):1851-1867. doi: 10.1161/CIRCULATIONAHA.116.026693. Review.

PMID:
28483832
45.

The future of atrial fibrillation management: integrated care and stratified therapy.

Kirchhof P.

Lancet. 2017 Oct 21;390(10105):1873-1887. doi: 10.1016/S0140-6736(17)31072-3. Epub 2017 Apr 28. Review. Erratum in: Lancet. 2017 Oct 21;390(10105):1832. Dosage error in article text.

PMID:
28460828
46.

Patient-centred care of patients with ventricular arrhythmias and risk of sudden cardiac death: What do the 2015 European Society of Cardiology guidelines add?

Norekvål TM, Kirchhof P, Fitzsimons D.

Eur J Cardiovasc Nurs. 2017 Oct;16(7):558-564. doi: 10.1177/1474515117702558. Epub 2017 Apr 4.

PMID:
28372463
47.

Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint.

Gwyn JCV, Thomas MR, Kirchhof P.

Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):157-162. doi: 10.1093/ehjcvp/pvx002. Review.

PMID:
28329215
48.

Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation.

Schnabel RB, Pecen L, Ojeda FM, Lucerna M, Rzayeva N, Blankenberg S, Darius H, Kotecha D, Caterina R, Kirchhof P.

Heart. 2017 Jul;103(13):1024-1030. doi: 10.1136/heartjnl-2016-310406. Epub 2017 Feb 22.

49.

PITX2-dependent gene regulation in atrial fibrillation and rhythm control.

Syeda F, Kirchhof P, Fabritz L.

J Physiol. 2017 Jun 15;595(12):4019-4026. doi: 10.1113/JP273123. Epub 2017 Apr 25. Review.

50.

Atrial high-rate episodes and stroke prevention.

Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M, Chlouverakis G, Diener HC, Kirchhof P.

Europace. 2017 Feb 1;19(2):169-179. doi: 10.1093/europace/euw279. Review.

Supplemental Content

Loading ...
Support Center